Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner

Thalidomide and its derivatives, lenalidomide and pomalidomide (also known as IMiDs), have significantly changed the treatment landscape of multiple myeloma, and the recent discovery of cereblon (CRBN) as their direct biological target has led to a deeper understanding of their complex mechanism of...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Mol Oncol
Главные авторы: Dimopoulos, Konstantinos, Søgaard Helbo, Alexandra, Fibiger Munch‐Petersen, Helga, Sjö, Lene, Christensen, Jesper, Sommer Kristensen, Lasse, Asmar, Fazila, Hermansen, Niels Emil Ulrich, O'Connel, Casey, Gimsing, Peter, Liang, Gangning, Grønbæk, Kirsten
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2017
Предметы:
Research Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5792743/
https://ncbi.nlm.nih.gov/pubmed/29130642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12157
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы